2020 年 46 巻 3 号 p. 146-152
Hydroxychloroquine (HCQ) is widely used around the world to manage diseases such as malaria, systemic lupus erythematosus (SLE), and rheumatoid arthritis. In Japan, its manufacture and sale were approved for cutaneous lupus erythematosus (CLE) and SLE in 2015.
We previously experienced a case of atrioventricular block with HCQ. Therefore, we investigated the usage of HCQ for CLE and SLE in our hospital. The subjects were nine patients, three of whom had had administration discontinued due to HCQ-induced adverse events (including adverse events suspected of being due to HCQ administration). Administration in Case 1 was suspended because of HCQ-induced drug eruption, but HCQ was resumed after symptomatic relief. In Case 2, sinus bradycardia was recognized by electrocardiography, and HCQ was temporarily stopped but later resumed. Administration in Case 3 was suspended because of cheilitis and eczema-like eruption. The number of days of administration until symptom onset (median [range]) in the three cases was 19 (13 - 106) days, and the adverse events described above were detected relatively early.
